Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope

Journal of Immunotherapy

Volumn 21, Issue 6, 1998, Pages 399-408

  Vierboom, Michel P M ^a   Feltkamp, Mariet C W ^b   Neisig, Anne ^a,c   Drijfhout, Jan Wouter ^a   Ter Schegget, Jan ^b   Neefjes, Jacques J ^c   Melief, Cornelis J M ^a   Martin Kast, W ^d  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Anchor replacement; Cytotoxic T lymphocytes; Human papillomavirus type 16; Peptide; Vaccine

Indexed keywords

CARRIER PROTEIN; EPITOPE; EUROPIUM; FREUND ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; VACCINATION; WART VIRUS;

EID: 0031758085     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199811000-00001     Document Type: Article

References (50)

1. Rötschke O, Falk K, Deres K, et al. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990;348:252-4.
2. Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined by short synthetic peptides. Cell 1986;44:959-68.
3. Van Bleek GM, Nathanson SG. Isolation of an endogenously processed immunodominant viral peptide from the H-2Kb molecule. Nature 1990;348:213-26.
4. Momburg F, Roelse J, Hämmerling GJ, Neefjes JJ. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J Exp Med 1994;179:1613-23.
5. Momburg FM, Roelse J, Howard GW, Butcher GW, Hämmerling GJ, Neefjes JJ. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 1994;367:648-52.
6. Schumacher TNM, Kantesaria DV, Heemels M-T, et al. Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J Exp Med 1994;179:533-40.
7. Van Bleek GM, Nathanson SG. The structure of the antigen-binding groove of MHC class I molecules determines specific selection of self peptides. Proc Natl Acad Sci USA 1991; 88: 11032-6.
8. Falk K, Rotschke O, Rammensee HG. Cellular peptide composition governed by major histocompatibility complex class I molecules. Nature 1990;348:248-51.
9. Falk K, Rotschke O, Stevanovic S, Jung G, Rammensee H-G. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-6.
10. Hunt DF, Henderson RA, Shabanowitz J, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-3.
11. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 1991;353:326-9.
12. Fremont DH, Matsumara M, Stura EA, Peterson PA, Wilson IA. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 1992;257:919-27.
13. Madden DR, Gorga JC, Strominger JL, Wiley DC. The threedimensional structure of HLA-B27 at 2.1 Â resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992; 70:1035-48.
14. Matsumara M, Fremont DH, Peterson PA, Wilson IA. Emerging principle for the recognition of peptide antigens by MHC class I molecules. Science 1992;257:927-34.
15. Zhang W, Young ACM, Imarai M, Nathanson SC, Sachettini JC. Crystal structure of the MHC class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T cell receptor recognition. Proc Natl Acad Sci USA 1992;89:8403-7.
16. Ruppert J, Sidney J, Cells E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-37.
17. Rohren EM, Pease LR, Pleogh HL, Schumacher TNM. Polymorphisms in pockets of MHC class I molecules influence peptide preference. J Exp Med 1993;177:1713-21.
18. Colbert RA, Rowland-Jones SL, McMichael AJ, Frelinger JA. Allele-specific B pocket transplant in class I MHC protein changes requirement for anchor residue at P2 of peptide. Proc Natl Acad Sci USA 1993;90:6879-83.
19. Jardetsky TS, Gorga JC, Busch R, Rothbard J, Strominger JL, Wiley DC. Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J 1990;9:1797-803.
20. Nijman HW, Houbiers JGA, Vierboom MPM, et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 1993;23:1215-9.
21. Bakker ABH, van der Burg SH, Huijbens RJF, et al. Analogues of CTL epitopes with improved MHC class I-binding capacity elicit anti-melanoma CTL recognizing the wild type epitope. Int J Cancer 1997;70:302-9.
22. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gplOO modified at HLA-A *0201-binding residues. J Immunol 1996;157:2539-48.
23. Feltkamp MCW, Smits HL, Vierboom MPM, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
24. Feltkamp MCW, Vreugdenhil GR, Vierboom MPM, et al. CTL raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 1995;25:2638-42.
25. Sadnikova E, Zhu X, Collins S, et al. Limitations of predictive motifs revealed by cytotoxic T lymphocyte epitope mapping of the human papillomavirus E7 protein. Int Immunol 1994;6:289-96.
26. Rotschke O, Falk K. Naturally-occurring peptide antigens derived from the MHC class-I restricted processing pathway. Immunol Today 1991;12:447-55.
27. Young ACM, Zhang W, Sacchettini JC, Nathanson S. The threedimensional structure of H-2Db at 2.4 A resolution: implications for antigen-determinant selection. Cell 1994;76:39-50.
28. Kast WM, Offringa R, Peters PJ, et al. Eradication of adenovirus El-induced tumors by ElA-specific cytotoxic T lymphocytes. Cell 1989;59:603-14.
29. Gorer PA. Studies in antibody response of mice to tumour inoculation. Br J Cancer 1950;4:372-81.
30. Ljunggren H-G, Öhlen C, Höglund P, Franksson L, Kärre K. The RMA-S lymphoma mutant; consequences of a peptide loading defect on immunological recognition and graft rejection. Int J Cancer 1991; 6(suppl):38-44.
31. Kast WM, Melief CJM. Fine peptide specificity of cytotoxic T lymphocytes against adenovirus-induced tumours and peptide-MHC binding. Int J Cancer 1991;6(suppl):90-4.
32. Neefjes JJ, Momburg F, Hämmerling GJ. Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 1993;261:769-71.
33. Neisig A, Roelse J, Sijts EJAM, et al. Major differences in TAP-dependent translocation of MHC class I presentable peptides and the effect of flanking sequences. J Immunol 1995;154:1273-9.
34. Bouma GJ, Van der Meer-Prins PMW, Van Bree FPMJ, Van Rood JJ, Claas FHJ. Determination of cytotoxic T-lymphocyte precursor frequencies using europium labeling as a nonradioactive alternative to labeling with chromium-51. Hum Immunol 1992;35:85-92.
35. Feltkamp MCW, Vierboom MPM, Ter Schegget J, Melief CJM, Kast WM. Fine characterization of the HPV16 E7 49-57 tumor protective cytotoxic T cell epitope “RAHYNIVTF”. In: Stanley M A. Immunology of human papillomaviruses, New York: Plenum Press, 275-81.
36. Feltkamp MCW, Vierboom MPM, Toes REM, et al. Competition inhibition of cytotoxic T lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than antibody-detected MHC class I stabilization. Immunol Lett 1995;47:1-8.
37. Villanueva MS, Fischer P, Feen K, Pamer EG. Efficiency of MHC class I antigen processing: a quantitative analysis. Immunity 1994; 1:479-89.
38. Bluestone JA, Jameson S, Miller S, Dick II R. Peptide-induced conformational changes in class I heavy chains alter MHC recognition. J Exp Med 1992;176:1757-61.
39. Catipovic B, Dal Porto J, Mage M, Johansen TE, Schneck JP. Major histocompatibility complex conformational epitopes are peptide specific. J Exp Med 1992;00:00-00.
40. Sette A, Sidney J, Del Guercio MF, et al. Peptide binding to the most frequent HLA-A alleles measured by quantitative molecular binding assays. Mol Immunol 1994;31:813-22.
41. Feltkamp MCW, Vierboom MPM, Kast WM, Melief CJM. Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. Mol Immunol 1994; 31:1391-401.
42. Lipford GB, Bauer S, Wagner H, Heeg K. Peptide engineering allows T-cell vaccination against human papilloma virus tumour antigen, E6. Immunology 1995;84:298-303.
43. Zur Hausen H. Human papillomavirus in the pathogenesis of anogenital cancer. Virology 1991;184:9-13.
44. Icenogle JP, Sathya P, Miller DL, Tucker RA, Rawls WE. Nucleotide and amino acid sequence variation in the LI and E7 open reading frames of human papillomavirus type 6 and type 16. Virology 1991;184:101-7.
45. Ho L, Chan SY, Burk RD, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient populations. J Virol 1993;67:6413-23.
46. Smits HL, Traanberg KF, Krul MRL, et al. Identification of a unique group of human papillomavirus type 16 sequence variants among clinical isolates from Barbados. J Gen Virol 1994;75: 2457-62.
47. Sijts EJAM, Ossendorp F, Mengede EAM, Van den Elsen PJ, Melief CJM. An immunodominant MCF murine leukemia virus encoded CTL epitope, identified by its MHC class I-binding motif, explains MuLV type specificity of MCF-directed CTL. J Immunol 1994;152:106-16.
48. Klenerman P, Rowland-Jones S, McAdam S, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 gag variants. Nature 1994;369:403-7.
49. De Magristis MT, Alexander J, Coggeshall M, et al. Antigen analog-major histocompatibility complex act as antagonists of the T cell receptor. Cell 1992;68:625-34.
50. Bertoletti A, Sette A, Chisari FV, et al. Natural variants of cytotoxic epitopes are T cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994;369:407-10.